Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Pregnancy, High Risk, Contraception
Interventions: Decision Aid, Routine Care; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 13 Years to 50 Years · Female only
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hiv, Substance Use Disorders
Interventions: Descovy 200Mg 25Mg Tablet, PrEP; Drug · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cancer Survivors
Interventions: Remote Assessment of Physical Function with Direct Observation, Remote Assessment of Physical Function; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 60 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Pain
Interventions: Ibuprofen 300 mg Oral Tablet, Ibuprofen 200 mg Oral Tablet, Placebo of PR tablet, Placebo of IR tablet; Drug
Lead sponsor: Reckitt Benckiser Healthcare (UK) Limited; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pulmonary Arterial Hypertension
Interventions: RVT-1201, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more

Conditions: Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
Interventions: alisertib, methotrexate, cisplatin, carboplatin, cyclophosphamide, etoposide, topotecan, vincristine, Surgical resection, Radiation therapy; Drug · Procedure · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 9
States / cities: Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more

Conditions: Episodic Migraine
Interventions: Atogepant, Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 34 more

Conditions: Hematopoietic Stem Cell Transplantation
Interventions: Ledipasvir 90mg/Sofosubvir 400mg; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Duarte, California • Los Angeles, California

Conditions: Asthma
Interventions: CXA-10, Placebo; Drug
Lead sponsor: Sally E. Wenzel MD; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatitis C, Human Immunodeficiency Virus
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more

Conditions: Waldenstrom Macroglobulinemia
Interventions: Pirtobrutinib, Venetoclax; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis (AD)
Interventions: ENV-294, Placebo; Drug
Lead sponsor: Enveda Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 3 more

Conditions: Hepatitis C, Cryoglobulinemia
Interventions: Harvoni, Epclusa; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more

Conditions: Sexually Transmitted Infections, Gay, Pre Exposure Prophylaxis
Interventions: Quantitative survey, HIV and STI testing, Qualitative Assessment; Behavioral · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 675 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: San Diego, California • Atlanta, Georgia • Chicago, Illinois

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Little Rock, Arkansas • Aventura, Florida • Greenacres City, Florida + 7 more

Conditions: Cardiovascular Disease, Interventional Cardiology
Interventions: Aspirin, Placebo, ticagrelor; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 9,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke, Transient Ischemic Attack
Interventions: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo, Placebo; Drug · Other
Lead sponsor: VITATOPS; Government
Eligibility: Not listed
Enrollment: 8,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 4
States / cities: New York, New York • Abington, Pennsylvania • Columbia, South Carolina

Conditions: Type 2 Diabetes, Impaired Renal Function
Interventions: Linagliptin, Placebo; Drug
Lead sponsor: George Washington University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Smoking Cessation
Interventions: Cytisinicline, Placebo, Behavioral support; Drug · Behavioral
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Mobile, Alabama • Phoenix, Arizona • Coral Gables, Florida + 14 more

Conditions: Colorectal Neoplasms
Interventions: pembrolizumab, lenvatinib, regorafenib, TAS-102 (trifluridine and tipiracil); Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Monterey, California • Marietta, Georgia • Chicago, Illinois + 8 more

Conditions: HIV-1 Infection
Interventions: Vesatolimod, Placebo, ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Ft. Pierce, Florida + 5 more

Conditions: HCV Infection
Interventions: SOF, RBV, LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois + 4 more

Search by objective public record fields.

Use of an Educational Multimedia Tool Versus Routine Care for the Uptake of Postpartum LARC in High-Risk Pregnancies

PrEP at a Syringe Services Program

Remote Assessment of Physical Function

Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine

Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.

Anti-Inflammatory Lipid Mediators in Asthma

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

HIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

VITATOPS: A Study of VITAmins TO Prevent Stroke

Linagliptin's Effect on CD34+ Stem Cells

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency